Tirzepatide – 2mg-100mg Bulk supply

Description

Tirzepatide

Tirzepatide is a high-purity synthetic peptide representing the latest breakthrough in endocrinology and metabolic research. Distinguished as a “twincretin,” Tirzepatide is a 39-amino acid modified peptide that functions as a dual agonist of the Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptors. Its unique molecular structure is based on the GIP amino acid sequence and includes a C20 fatty diacid moiety, which significantly extends its biological half-life and enhances its potency. In complex metabolic models, Tirzepatide integrates the signaling pathways of both incretins to Investigation the synergistic effects on insulin secretion, glucagon suppression, and appetite regulation. It provides researchers with an unparalleled experimental tool to study the reversal of Type 2 diabetes markers, the molecular dynamics of chronic weight management, and systemic cardiovascular metabolic health.

Our Tirzepatide is produced in an ISO 9001:2015 certified environment utilizing high-precision Solid-Phase Peptide Synthesis (SPPS) and advanced acylation technology. We achieve an ultra-high chemical purity of ≥99%, verified by HPLC and Mass Spectrometry (MS). This rigorous production standard ensures the peptide is free from truncated variants and residual chemical catalysts, guaranteeing the high-fidelity data required for longitudinal metabolic studies and energy homeostasis research.

Research Applications & Mechanisms

Dual-Pathway Incretin Signaling

Investigating the synergistic activation of GIP and GLP-1 receptors to study the optimization of glucose-dependent insulinotropic responses.

Advanced Adipose Tissue Metabolism

Researching the influence of dual agonism on lipid oxidation and investigating the reduction of ectopic fat accumulation in metabolic research designs.

Central Satiety & Energy Balance

Studying the mechanisms through which Tirzepatide modulates hypothalamic hunger signaling to promote a significant reduction in caloric intake.

Cardiovascular & Renal Protective Pathways

Exploring the potential impact of long-acting incretin mimetics on the protection of vascular integrity and renal function in chronic research models.

Technical Specifications

Key Features & Quality Assurance

Pharmaceutical-Grade Lyophilization Stability

Our proprietary vacuum-sealing process ensures the Tirzepatide powder surface is perfectly smooth, flat, and delicate. This uniform “cake” structure ensures rapid, clear reconstitution and maintains the molecular stability of the acylated peptide during long-term storage.

High-Fidelity Sequence Verification

Every batch undergoes strict Mass Spectrometry (MS) to confirm the exact amino acid sequence and the integrity of the C20 fatty acid side chain, ensuring reproducible results in high-stakes metabolic signaling assays.

Reconstitution & Storage

Reconstitution Guide

• Preparation: Allow the vial to reach room temperature. Centrifuge for 30-60 seconds to ensure the Tirzepatide cake is at the base.

• Solvent: Reconstitute with Sterile Water or Bacteriostatic Water.

• Technique: Gently introduce the diluent against the vial wall. DO NOT SHAKE; swirl gently until the solution is clear and transparent.

Storage Protocols

• Long-term: Store at -20°C (Maintains potency for up to 24 months).

• Short-term: Stable at 2–8°C for up to 3 months.

• Post-Reconstitution: Store at 2–8°C and utilize within 14-21 days for optimal research results.

Shipping & Documentation

• Global Logistics: Shipped in discreet, temperature-controlled packaging to maintain the structural integrity of the Tirzepatide peptide.

• Verified Quality: A batch-specific COA and HPLC/MS reports are available for every order.

• Reshipment Policy: We provide a guaranteed reshipment policy for any lost or customs-intercepted orders (terms apply).

⚠️ Research Disclaimer

Product-Specific Safety Notice: This Tirzepatide is strictly for laboratory research and analytical purposes. It is NOT intended for human or veterinary administration. All research must be conducted by qualified professionals.

Scientific Resources & References

• National Center for Biotechnology Information (NCBI): Compound Summary – Tirzepatide (GLP-1 / GIP dual receptor agonist)

• PubMed – NIH: Clinical studies on Tirzepatide in type 2 diabetes and obesity (SURPASS trials)